Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...

The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...

Rare diseases have become an attractive target for pharmaceutical companies both on the ASX and internationally.

The approach requires balance, however. There is the risk of increased AEs, as well as financial toxicity. Friedlander shared ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Request To Download Free Sample of This Strategic Report@ Highlighted with 148 tables and 111 figures, this 241-page report ?Global Clinical Trials Market 2022-2031 by Product Category (Drugs, ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 99 tables and 79 figures, this 186-page report ?Europe Clinical Trials Market 2022-2031 by Product Category (Drugs, Devices ...

Automation in drug discovery is no longer nice. It’s becoming the backbone of modern labs. Meghav has been central to this shift, leading projects that make complex workflows more manageable. His ...

Bristol Myers Squibb’s LAG-3 blocker Opdualag came up short in the Phase III RELATIVITY-098 study ... BMS has also enacted sweeping cost cuts to help its balance sheet, including the $1.5-billion ...

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

Once selected, Quris can in-license them, progress them through to phase 1 trials and ... by these systems then the overall drug development cost and timeline could be vastly reduced, as well ...

The Alzheimer’s Association hailed the development ... A six-month course would cost $12,522 while the drug would cost $48,696 for patients who need to stay on it for 18 months.